Abstract:
The disclosure pertains to antibodies and binding fragments thereof that specifically binds all or part of EHAEVVFTA. Also provided are isolated peptides, isolated nucleic acids, immunogens, compositions, immunoassays and kits and method of using said reagents to detect misfolded TTR.
Abstract:
A method and imaging system for operating imaging computed tomography using at least one radiation source and at least one detector to generate an image of an object. The method includes: defining desired image characteristics; and performing calculations to determine the pattern of fluence to be applied by the at least one radiation source, to generate said desired image quality or characteristics. Then, the at least one radiation source is modulated, to generate the intended pattern of fluence between the beam source and the object to be imaged. The desired image characteristics can provide at least one of: desired image quality in at least one defined region of interest; and at least one desired distribution of said image quality.
Abstract:
The disclosure pertains to antibodies and binding fragments thereof that specifically binds all or part of EHAEVVFTA. Also provided are isolated peptides, isolated nucleic acids, immunogens, compositions, immunoassays and kits and method of using said reagents to detect misfolded TTR.
Abstract:
Provided are methods and products for obtaining cardiovascular lineage cells from hPSCs. The method for obtaining a cardiomyocyte lineage or an epicardial lineage cell population from human pluripotent stem cells (hPSCs) comprises one or more of the following steps: (a) contacting BMP component primed hPSCs with a cardiovascular mesoderm programming cocktail suitable for inducing the hPSCs to differentiate to a cardiovascular mesoderm cell population under conditions suitable for the programming cocktail to penetrate the hPSCs and culturing the contacted hPSCs for a period of time to generate a KDR+ and PDGFRalpha+ cardiovascular mesoderm cell population; (b) contacting the cardiovascular mesoderm cell population with a cardiovascular progenitor specification cocktail suitable to specify a NKX2-5+ or WT1+ cardiovascular progenitor cell population under conditions suitable for the specification cocktail to penetrate the cardiovascular mesoderm cell population and culturing the contacted cardiovascular mesoderm cell population for a period of time to generate a NKX2-5+ or WT1+ cardiovascular progenitor cell population; and (d) contacting the cardiovascular progenitor cell population with a maturation cocktail under conditions suitable for the maturation cocktail to penetrate the cardiovascular progenitor cell population and culturing the contacted cardiovascular progenitor population for a period of time to produce a cardiovascular population optionally cardiomyocyte lineage cells expressing cardiac troponin T (cTnT) and/or SIRPA and/or epicardial lineage cells expressing WT1.
Abstract:
There is provided herein a method for categorizing a patient having inflammatory bowel disease as being at risk for developing ankylosing spondylitis. The method comprises the use of a patient level of auto-antibodies directed against noggin (NOG) and/or sclerostin (SOST) to determine a risk for the patient developing ankylosing spondylitis. There is also provided methods of monitoring ankylosing spondylitis treatment using these auto-antibodies.
Abstract:
There is provided signal modifying compositions for medical imaging comprising a carrier and signal modifying agents specific for two or more imaging modalities. The compositions are characterized by retention efficiency, with respect of the signal modifying agents that enables prolonged contrast imaging without significant depletion of the signal modifying agent from the carrier. The carriers of the present invention are lipid based or polymer based the physico-chemical properties of which can be modified to entrap or chelate different signal modifying agents and mixtures thereof and to target specific organs or tumors or tissues within a mammal.
Abstract:
The biopsy device generally comprises: a cannula body having a longitudinal axis and a probing region extending along the longitudinal axis, the probing region having a sample receiving window defined therein for receiving a sample of a surrounding tissue when performing a biopsy; and a plurality of optical fibers mounted along an exterior portion of the cannula body, each of the plurality of optical fibers having a fiber end in the probing region of the cannula body, at least one of the plurality of optical fibers being adapted to illuminate the surrounding tissue with an optical signal generated by the at least one light generator and at least one of the plurality of optical fibers being adapted to detect an optical signal response with the at least one light detector, the optical signal response being caused by the propagation of the optical signal in the surrounding tissue.
Abstract:
There is provided herein a method for categorizing a patient having inflammatory bowel disease as being at risk for developing ankylosing spondylitis. The method comprises the use of a patient level of auto-antibodies directed against noggin (NOG) and/or sclerostin (SOST) to determine a risk for the patient developing ankylosing spondylitis. There is also provided methods of monitoring ankylosing spondylitis treatment using these auto-antibodies.
Abstract:
A method and apparatus for providing functional electrical stimulation to an individual for altering a mood or emotional parameter associated with a mood or emotional state is provided. The method involves providing functional electrical stimulation to facial muscles of the individual so as to elicit a detectable contraction in said muscles associated with a facial expression associated with a desired mood or emotional parameter.